These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26196746)

  • 41. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
    van Bree C; Castro Kreder N; Loves WJ; Franken NA; Peters GJ; Haveman J
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):237-44. PubMed ID: 12182997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
    Kocabas NA; Aksoy P; Pelleymounter LL; Moon I; Ryu JS; Gilbert JA; Salavaggione OE; Eckloff BW; Wieben ED; Yee V; Weinshilboum RM; Ames MM
    Drug Metab Dispos; 2008 Sep; 36(9):1951-9. PubMed ID: 18556440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
    Kao YT; Hsu WC; Hu HT; Hsu SH; Lin CS; Chiu CC; Lu CY; Hour TC; Pu YS; Huang AM
    Kaohsiung J Med Sci; 2014 Jul; 30(7):323-30. PubMed ID: 24924837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK.
    He Q; Zheng Y; Lu L; Shen H; Gu W; Yang J; Zhang X; Jin H
    Heliyon; 2024 Apr; 10(7):e28488. PubMed ID: 38590861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
    Blackstock AW; Lightfoot H; Case LD; Tepper JE; Mukherji SK; Mitchell BS; Swarts SG; Hess SM
    Clin Cancer Res; 2001 Oct; 7(10):3263-8. PubMed ID: 11595723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
    Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
    J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
    Pauwels B; Korst AE; Pattyn GG; Lambrechts HA; Kamphuis JA; De Pooter CM; Peters GJ; Lardon F; Vermorken JB
    BMC Cancer; 2006 May; 6():142. PubMed ID: 16734894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
    Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
    Sigmond J; Kroep JR; Loves W; Codacci-Pisanelli G; Peters GJ
    Cancer Lett; 2004 Sep; 213(2):173-9. PubMed ID: 15327832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
    Yao J; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):721-6. PubMed ID: 16483481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
    Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
    J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
    Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
    Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
    Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
    Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.